Bradley J. Monk
Expertise in
13
conditions

Dr. Bradley J. Monk

Gynecologic Oncology | Oncology
1309 N Flagler Dr, 
West Palm Beach, FL 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
1309 N Flagler Dr, 
West Palm Beach, FL 

Overview

Bradley Monk is an Oncologist in West Palm Beach, Florida. Dr. Monk is highly rated in 13 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy. Dr. Monk is currently accepting new patients.

His clinical research consists of co-authoring 350 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Arizona College Of Medicine

Specialties

Gynecologic Oncology
Oncology

Licenses

Obstetrics & Gynecology in FL

Board Certifications

American Board Of Obstetrics & Gynecology

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Florida Cancer Specialists Pl
1309 N Flagler Dr, West Palm Beach, FL 33401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Afuresertib
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Rucaparib, Nivolumab
Study Phase: Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2024
Intervention Type: Diagnostic test, Drug
Study Drug: Standard Chemotherapy
Study Phase: Phase 3
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
Enrollment Status: Completed
Publish Date: February 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 19 Less Clinical Trials

350 Total Publications

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Journal: JCO precision oncology
Published: January 14, 2026
Similar Doctors
Expertise in
13
conditions
Dr. Michael Worley
Gynecologic Oncology | Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Michael Worley
Gynecologic Oncology | Obstetrics and Gynecology

The Anderson Family Cancer Institute

1240 S Old Dixie Hwy, 
Jupiter, FL 
 (13.9 miles away)
561-263-4400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Worley is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Jupiter, Florida. Dr. Worley is highly rated in 13 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Ureteroscopy.

Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology
Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology

Memorial Cancer Institute

12235 Pines Blvd, 
Pembroke Pines, FL 
 (50.6 miles away)
954-869-5708
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist and an Oncologist in Pembroke Pines, Florida. Dr. Raez is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Expertise in
87
conditions
Dr. Abraham Schwarzberg
Hematology | Oncology
Expertise in
87
conditions
Dr. Abraham Schwarzberg
Hematology | Oncology

Tampa General Hospital Cancer Center South Florida - Palm Beach

11621 Kew Gardens Ave Ste 101A, 
Palm Beach Gardens, FL 
 (8.6 miles away)
813-302-1571
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abraham Schwarzberg is a Hematologist and an Oncologist in Palm Beach Gardens, Florida. Dr. Schwarzberg is highly rated in 87 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Schwarzberg is currently accepting new patients.

Frequently Asked Questions about Dr. Bradley J. Monk

How do I make an appointment with Dr. Bradley J. Monk?

You can book an appointment with Dr. Bradley J. Monk by calling their office at 561-366-4100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bradley J. Monk a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bradley J. Monk is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bradley J. Monk specialize in?

While Dr. Bradley J. Monk is a Gynecologic Oncology, they have specific expertise in Ovarian Cancer, Cervical Cancer, and Endometrial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gynecologic Oncology.

Does Dr. Bradley J. Monk participate in research or clinical trials?

Yes. Dr. Bradley J. Monk has published 350 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Bradley J. Monk's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bradley J. Monk accept my insurance?

Dr. Bradley J. Monk accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 561-366-4100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Monk's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile